Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

SOP for Root Cause Analysis in Transdermal Patches Production

Posted on By

SOP for Root Cause Analysis in Transdermal Patches Production

Standard Operating Procedure for Root Cause Analysis in Transdermal Patches Production

1) Purpose

To establish a procedure for conducting root cause analysis (RCA) in the production of transdermal patches to identify and address the underlying causes of quality issues.

2) Scope

This SOP applies to all personnel involved in the production, quality control, and quality assurance of transdermal patches.

3) Responsibilities

3.1 Production Department: Responsible for reporting any issues to QA.
3.2 Quality Assurance (QA) Department: Responsible for overseeing RCA process.
3.3 Quality Control (QC) Department: Provides data and analysis for RCA.
3.4 RCA Team: Cross-functional team including representatives from QA, Production, and QC.

See also  SOP for Validation of Analytical Methods for Transdermal Patches

4) Procedure

4.1 Issue Identification:

4.1.1 Identify and document quality issues, deviations, or non-conformances related to transdermal patches.

4.1.2 Report issues to QA for further investigation.

4.2 RCA Team Formation:

4.2.1 Form an RCA team with relevant stakeholders.

4.2.2 Assign a team leader responsible for coordinating RCA activities.

4.3 RCA Methodology:

4.3.1 Use tools like Fishbone Diagrams, 5 Whys, or Fault Tree Analysis to identify root causes.

4.3.2 Gather data from production records, testing results, and

observations.

4.4 Root Cause Identification:

4.4.1 Analyze data to determine root cause(s) contributing to the issue.

4.4.2 Document findings in the RCA report.

4.5 CAPA Implementation:

See also  SOP for Freeze-Thaw Stability Testing for Transdermal Patches

4.5.1 Develop corrective actions to address identified root causes.

4.5.2 Implement preventive actions to prevent recurrence.

4.6 RCA Report Review:

4.6.1 Review and approve the RCA report.

4.6.2 Ensure all actions are implemented and effective.

4.7 Documentation:

4.7.1 Maintain RCA report and related documents for record-keeping.

4.7.2 Periodically review RCA findings for continuous improvement.

5) Abbreviations, if any

SOP: Standard Operating Procedure
RCA: Root Cause Analysis
CAPA: Corrective and Preventive Actions
QA: Quality Assurance
QC: Quality Control

6) Documents, if any

RCA Report
Production Records
Testing Results
CAPA Plan

7) Reference, if any

ICH Q9: Quality Risk Management
ISO 9001: Quality management systems – Requirements
FDA Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production

See also  SOP for Recall Procedure for Transdermal Patches

8) SOP Version

Version 1.0

Transdermal Patches Tags:Adhesion Testing Protocol, Analytical Method Development SOP, Assay of Active Ingredient SOP, Contamination Prevention SOP, Documentation SOP, Equipment calibration SOP, Equipment Cleaning SOP, Final Product Inspection SOP, Formulation development SOP, Homogeneity Testing SOP, In-process Testing SOP, Microbial Testing SOP, Personnel Training SOP, Process Optimization SOP, Process Validation SOP, Quality Control Transdermal Patches, Raw Material Inspection SOP, Release Rate Testing SOP, Sample Collection SOP, Sterility Maintenance SOP, Storage Conditions Transdermal Patches, Thickness Testing Procedure, Transdermal Patch Manufacturing SOP, Transdermal Patch Stability Testing, Waste Handling SOP

Post navigation

Previous Post: SOP for Corrective and Preventive Actions (CAPA) in Transdermal Patches Production
Next Post: SOP for Risk Management in Transdermal Patches Production

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version